 BOSTON, Sept. 23, 2021 PRNewswire -- Stealth BioTherapeutics Corp Nasdaq: MITO, a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today the presentation of new promising data from a study evaluating the effects of SBT-272 in a murine model of Parkinsons disease PD. 